hymatil
industrial veterinaria -
ceftiocyl flow
vetoquinol sa magny -
ceftiosan 50mg-ml
eficur
laboratorios hipra -
amoksiklav 500 mg-g + 125 mg-g (62,5%)
elanco gmbh -
clindabactin
dechra regulatory -
dectomax
zoetis belgium -
klavuxil susp.za injiciranje
genera si -
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastiki - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.